Holen Sie sich die Stockscreener-App
20.00
16.55%
2.84
Vorhandelsmarkt:
20.25
0.25
+1.25%
Dbv Technologies Adr Aktie (DBVT) Neueste Nachrichten
European Companies Trading In The US Notched Gains This Week - Finimize
BETA Technologies Inc (BETA) Performance and Fundamentals Dashboard tells a completely different story - Setenews
Are Smart Investors Making the Right Decision? Snow Lake Resources Ltd (LITM) - Setenews
Total assets of DBV Technologies SA Sponsored ADR – LSX:A40WEX - TradingView
DBV Technologies (NASDAQ:DBVT) Coverage Initiated at Guggenheim - Defense World
Check Out Netskope Inc (NTSK)’s Trade Data Rather Than the Analysts’ Views - Setenews
Taking on analysts’ expectations and winning: DBV Technologies ADR (DBVT) - Setenews
DBV Technologies stock initiated with Buy rating at Guggenheim - Investing.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
Healthy Upside Potential: Safe Pro Group Inc (SPAI) - Setenews
DBV Technologies S.A. (NASDAQ:DBVT) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
RFK Jr Rejects Early Exposure Theory On Rising Peanut Allergies, Says Aluminum-Based Vaccines Are The Reason - Sahm
European ADRs Slip As Gains And Losses Balance Out - Finimize
US Investors Show Renewed Interest In European ADRs - Finimize
Pre Market Movers: SLRX, SI, ELDN Swing Big - RTTNews
Why LightPath Technologies Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket - inkl
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years - The Manila Times
DBV Technologies (NASDAQ: DBVT) marks last patient visit in 654-patient VITESSE study - Stock Titan
DBV Technologies Announces Last Patient Visit Completed in - GlobeNewswire
DBV Technologies annonce la dernière visite du dernier patient dans l'essai clinique de phase 3 VITESSE du patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques aux arachides - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), ALX Oncology Holdings (ALXO) and Cencora (COR) - The Globe and Mail
DBV technologies S.A. (ADR) (DBV1.SG) Balance Sheet - Yahoo! Finance Canada
Biotech Shines As UK And European ADRs See Mixed Results - Finimize
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - The Manila Times
DBV (NASDAQ: DBVT) to join Guggenheim Healthcare Innovation Conf.; webcast, 90-day replay - Stock Titan
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer - 24matins.uk
DBV Technologies (NASDAQ: DBVT) appoints Kevin Trapp to lead Viaskin Peanut commercialization - Stock Titan
European ADRs Show Mixed Moves In Active Sectors - Finimize
DBV Technologies Appoints Dr. Philina Lee to Board - The Globe and Mail
DBV Technologies Reports Q3 2025 Financial Results - MSN
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors - The Manila Times
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting - The Manila Times
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq - markets.businessinsider.com
Health Care And Telecom Drive European ADR Gains In The US - Finimize
European ADRs Mostly Flat As Gains And Losses Trade Off - Finimize
DBV Technologies Announces Sale of approximately $30 - GlobeNewswire
DBV Technologies (NASDAQ: DBVT) sells ~$30M in ADSs; dilution ~5.96% - Stock Titan
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):